Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 390-396

  Eisenkop, Scott M ^a   Spirtos, Nick M ^b   Friedman, Richard L ^c   Lin, Wei Chien Michael ^a   Pisani, Albert L ^d   Perticucci, Sergio ^e  

^a Departments of Pathology   (United States)

^b Womens' Cancer Center: Palo Alto   (United States)

^c Queen Angels Hollywood Presbyt Med   (United States)

^d San Diego Cancer Regional Center   (United States)

^e Bakersfield Family Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ABDOMEN; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PELVIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0041622805     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00278-6     Document Type: Article

References (29)

1. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Natl Cancer Inst Monogr. 42:1978;131-136.
2. Alberts D.S., Liu P.Y., Hannigan E.V., O'Tolle R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B., Adelson M.D., Hoskins W.J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
3. Makar A.P., Baekelandt M., Trope' C.G., Kristensen G.B. The Prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 56:1995;175-180.
4. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., Wang H. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 47:1992;203-209.
5. Le T., Krepart G.V., Lotocki R.J., Heywood M.S. Does debulking surgery improve survival in biologically aggressive ovarian cancer. Gynecol Oncol. 67:1997;208-214.
6. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxirubicin in ovarian carcinoma a gynecologic oncology group study . J Clin Oncol. 7:1989;457-465.
7. Eisenkop S.M., Friedman R.L., Wang H. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer a prospective study . Gynecol Oncol. 69:1998;103-106.
8. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L.S., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era a meta-analysis . J Clin Oncol. 20:2002;1248-1259.
9. Heintz A.P., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., Lagasse L.D. Cytoreductive surgery in ovarian carcinoma feasibility and morbidity . Obstet Gynecol. 67:1986;783-788.
10. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 78:2000;269-274.
11. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer a Gynecologic Oncology Group Study . Gynecol Oncol. 47:1992;167-171.
12. Potter M.E., Partridge E.E., Hatch K.D., Soong S., Austin J.M., Shingelton H.M. Primary surgical therapy for ovarian cancer how much and when . Gynecol Oncol. 40:1992;195-200.
13. Jaeger W., Ackermann S., Kessler H., Katalinic A., Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 83:2001;286-291.
14. Eisenkop S.M., Spirtos N.M. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol. 82:2001;143-149.
15. Eisenkop S.M., Spirtos N.M. Procedures required to accomplish complete cytoreduction for ovarian cancer. Is there a correlation with "biological aggressiveness" and survival. Gynecol Oncol. 82:2001;435-441.
16. Montz F.J., Schlaerth J.B., Berek J.S. Resection of diaphragmatic peritoneum and muscle role in cytoreductive surgery for ovarian cancer . Gynecol Oncol. 35:1989;338-340.
17. Eisenkop S.M., Nalick R.H., Wang H., Teng N.N.H. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer impact on survival . Gynecol Oncol. 51:1993;224-229.
18. Bristow R.E., Montz F.J. Complete surgical cytoreduction for advanced ovarian carcinoma using the Argon Beam Coagulator. Gynecol Oncol. 83:2001;39-48.
19. Eisenkop S.M., Nalick R.H., Teng N.N.H. Modified posterior exenteration for ovarian cancer. Obstet Gynecol. 78:1991;879-885.
20. Rose P.G. The cavitronal ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol. 166:1992;843-846.
21. Deppe G., Maliviya V.K., Malone J.M. Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA) - a preliminary report. Gynecol Oncol. 31:1988;223-226.
22. Spirtos N.M., Gross G.M., Freddo J.L., Ballon S.C. Cytoreductive surgery in advanced epithelial cancer of the ovary the impact of aortic and pelvic lymphadenectomy . Gynecol Oncol. 56:1995;345-352.
23. Benedetti-Panici P., Scambia G., Baiocchi G. Technique and feasibility of radical para-aortic and pelvic lymphadenectomy for gynecologic malignancies a prospective study . Int J Gynecol Cancer. 133:1991;1-6.
24. Eisenkop S.M., Spirtos N.M. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer. Gynecol Oncol. 82:2001;489-497.
25. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., Elashoff R.M. Primary cytoreductive surgery for ovarian cancer. Obstet Gynecol. 61:1983;413-420.
26. Farias-Eisner R., Teng R., Olivera M., Leuchter R., Karlan B., Lagasse L., Berek J.S. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 55:1994;108-110.
27. Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., Hoskins W.J. Identification of prognostic factors in advanced ovarian carcinoma. Gynecol Oncol. 82:2001;532-537.
28. Naik R., Nordin A., Cross P.A., Hemming D., Lopes A.B., Monaghan J.M. Complete cytoreduction is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease . Gynecol Oncol. 78:2000;176-180.
29. Prefontaine M., Gelfand A.T., Donavan J.T., Powell J.L. Reproducibility of tumor measurements in ovarian cancer a study of interobserver variability . Gynecol Oncol. 66:1994;87-90.